UPDATED: Amgen halts a PhI for FLT3 BiTE while resuming dosing on another
Amgen did a bit of a balancing act for its column of Phase I oncology programs during the latest quarterly update, as it disclosed that it’s resumed dosing for pavurutamab (AMG 710) but halted enrollment to a trial for AMG 427. Both were BiTE molecules with extended half lives.
Alarmed by a safety issue that they’ve encountered, scientists are tweaking the protocol before they can resume dosing, a spokesperson told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.